A major step and a critical milestone achieved prior to First In Human clinical trials FineHeart’s TET is a system
– SoniVie Acquires New Intellectual Property and Other Assets from Cardiosonic Moving TIVUS into New Therapeutic Areas Beyond Pulmonary Hypertension
French-Canadian biotech company has nominated DT-9081 as development candidate and launched CMC activities • DT-9081 will be combined with immune
Paris, November 23, 2020 – PKvitality, a French company specialized in bio wearables, has been rewarded by being named the
– International study designed to build on positive 12-month data from TROPHY1 demonstrating improvement in multiple clinical endpoints and no
French biotech company will use its bioSens-All proprietary technology to correlate impact of GPCR mutations on signaling pathways Results may
Towards a new standard for device indication: Implantation for temporary or permanent use • Easy removal with a beating heart
Karista invests in MyPL increasing its financing to €1.8m & accelerating its development
by Jean-Alexandre Kaminisky, 2021-03-18 Karista invests in MyPL increasing its financing to €1.8m & accelerating its development Paris – France, March
by Jean-Alexandre Kaminisky, 2021-03-16 MyPL wins €1.1 Million European Union grant as part of Horizon Europe 2020 GerOnTe[1] project out of a
Latest Insights
– SoniVie Acquires New Intellectual Property and Other Assets from Cardiosonic Moving TIVUS into New Therapeutic Areas Beyond Pulmonary Hypertension
Paris, November 6th, 2019 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA,CANADA, AUSTRALIA AND JAPAN The first connected all-in-one Diabetes Management System Paris,
Paris, July 1st, 2021 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases,
A major step and a critical milestone achieved prior to First In Human clinical trials FineHeart’s TET is a system